Dr. Yeun-Hee A. Park
Claim this profileJames J Peters VA Medical Center
Area of expertise
Lung Cancer
Yeun-Hee A. Park has run 4 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Yeun-Hee A. Park has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
James J Peters VA Medical Center
Clinical Trials Yeun-Hee A. Park is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Olanzapine vs Megestrol Acetate
for Cancer-Related Anorexia
This trial tests whether olanzapine or megestrol acetate is better at increasing appetite in patients with advanced cancer. These patients often struggle with eating and weight loss. Both medications aim to make them feel hungrier, helping them eat more and gain weight. Megestrol acetate is known for its effectiveness in increasing appetite in patients with cancer.
Recruiting
2 awards
Phase 3
1 criteria
More about Yeun-Hee A. Park
Clinical Trial Related
11 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Yeun-Hee A. Park has experience with
- Biospecimen Collection
- Carboplatin
- Pembrolizumab
- Crizotinib
- Data Collection
- Quality-of-Life Assessment
Breakdown of trials Yeun-Hee A. Park has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Anaplastic Large Cell Lymphoma
ALK Gene Rearrangement
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yeun-Hee A. Park specialize in?
Yeun-Hee A. Park focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage II.
Is Yeun-Hee A. Park currently recruiting for clinical trials?
Yes, Yeun-Hee A. Park is currently recruiting for 2 clinical trials in Bronx New York. If you're interested in participating, you should apply.
Are there any treatments that Yeun-Hee A. Park has studied deeply?
Yes, Yeun-Hee A. Park has studied treatments such as Biospecimen Collection, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Yeun-Hee A. Park?
Apply for one of the trials that Yeun-Hee A. Park is conducting.
What is the office address of Yeun-Hee A. Park?
The office of Yeun-Hee A. Park is located at: James J Peters VA Medical Center, Bronx, New York 10468 United States. This is the address for their practice at the James J Peters VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.